Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2022 | NeoPeLe: neoadjuvant pembrolizumab and lenvatinib in resectable stage III melanoma

Georgina Long, BSc, PhD, MBBS, FRACP, FAHMS, The University of Sydney, Sydney, Australia, discusses the results of the NeoPeLe trial (NCT04207086), a Phase II trial of neoadjuvant pembrolizumab combined with lenvatinib in resectable stage III melanoma. A high pathological complete response and pathological response rate was observed with neoadjuvant pembrolizumab and lenvatinib, higher than previous studies of PD1 alone. The trial and translational investigations are ongoing, and relapse-free survival and overall survival data will be collected. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.